Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer

(MedPage Today) -- Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced ovarian cancer, a large randomized trial showed.
In fact, median progression-free survival...